Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.

[1] This drug was developed by Medarex, which was later acquired by Bristol-Myers Squibb.

The FDA granted orphan drug designation for Hodgkin's lymphoma in 2004.

In 2009, development was suspended with no explanation given.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.